APOE and ovarian carcinoma: In ApoE ε4 carriers, there were five deaths (2.3 %) in the placebo + bapineuzumab 0.5 group (cardiac failure, metastases to lymph nodes, ovarian cancer, pancreatic carcinoma, subarachnoid hemorrhage) and two deaths (0.7 %) in the bapineuzumab 0.5 + bapineuzumab 0.5 group (cardiac failure congestive and cardiomyopathy).